Anti-Transforming growth factor beta receptor II Antibody, Non-Fucosylated (DOM23h-271-21) (CAT#: BioBet-1340ZP) Datasheet

TGFBR2

transforming growth factor, beta receptor II (70/80kDa)

This gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized.

TGFBR2; transforming growth factor, beta receptor II (70/80kDa); AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFbeta-RII; TGF-beta receptor type-2; tbetaR-II; TGF-beta type II receptor; TGF-beta receptor type IIB; transforming growth factor beta receptor type IIC; transforming growth factor, beta receptor II beta; transforming growth factor, beta receptor II alpha; transforming growth factor, beta receptor II delta; transforming growth factor, beta receptor II gamma; transforming growth factor, beta receptor II epsilon

Plasma membrane

Diseases associated with TGFBR2 include Loeys-Dietz Syndrome 2 and Colorectal Cancer, Hereditary Nonpolyposis, Type 6.

Its related pathways are Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer and Transcriptional misregulation in cancer.

Transmembrane serine/threonine kinase forms with the tgf-I type serine/threonine kinase receptor TGFBR1, a non-hybrid receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. It can sense TGFB1, TGFB2 and TGFB3 signals from the cell surface to the cytoplasm, thus regulating a variety of physiological and pathological processes including epithelial cell cycle arrest and control of hematopoietic and mesenchymal cell proliferation and differentiation, wound healing, and extracellular matrix production , Immunosuppressive and carcinogenic effects. The formation of a receptor complex composed of two TGFBR1 and two TGFBR2 molecules symmetrically bound to the cytokine dimer results in phosphorylation of the active TGFBR2 and activation of TGFRB1. Activated TGFBR1 phosphorylates SMAD2, and SMAD2 separates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is then transferred to the nucleus, where it regulates the transcription of tgf-regulated genes. This constitutes a typical smad-dependent tgf signal cascade. It also participates in the atypical, smad-independent TGF-beta signaling pathway.

Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

DOM23h-271-21

Humanized

Human

The antibody against human transforming growth factor beta receptor II (TGFβRII) are used for treating cancer and fibrosis.

Cancer; Fibrosis

Cancer; Fibrosis